智通财经APP获悉，周二，Beyond Meat(BYND.US)股价一度跌超9%，截至发稿，该股跌幅收窄至 2.15%，报1.32美元。Beyond Meat第三季度净收入同比下降13.3%至7020万美元，但略高于分析师平均 预期6900万美元。亏损扩大至1.107亿美元，受累于资产减值损失以及今年稍早暂停在中国的业务；每 股亏损47美分，低于分析师预期的每股亏损31美分。该公司预计第四季收入将介乎6000万至6500万美元 之间，低于市场预期的7003万美元。 ...

"人造肉第一股"Beyond Meat(BYND.US)跌9.7%，报1.21美元。消息面上，Beyond Meat第三季度净收入 同比下降13.3%至7020万美元，但略高于分析师平均预期6900万美元。亏损扩大至1.107亿美元，受累于 资产减值损失以及今年稍早暂停在中国的业务；每股亏损47美分，低于分析师预期的每股亏损31美分。 该公司预计第四季收入将介乎6000万至6500万美元之间，低于市场预期的7003万美元。(格隆汇) ...

Core Insights - Beyond Meat's stock dropped over 8.2% in after-hours trading, closing at $1.23 [1] - The company reported a 13.3% year-over-year decline in net revenue to $70.2 million, slightly above analyst expectations of $69 million [1] - Losses widened to $110.7 million, impacted by asset impairment losses and a pause in operations in China earlier this year [1] - Earnings per share (EPS) loss was $0.47, worse than the analyst forecast of a $0.31 loss per share [1] - For Q4, the company expects revenue between $60 million and $65 million, below the market expectation of $70.03 million [1]

Core Viewpoint - Beyond Meat, known as the "first stock of plant-based meat," experienced a significant decline of over 16% on Monday, with a pre-market drop of more than 8.6%, bringing its share price down to $1.27 [1] Summary by Relevant Sections - Financial Performance - Beyond Meat announced a delay in the release of its third-quarter financial report to November 11, after market close [1] - The delay is attributed to the need for additional time to calculate significant non-cash impairment charges related to certain long-term assets [1]

Core Viewpoint - Beyond Meat has announced a delay in the release of its third-quarter financial report to quantify an impairment loss, leading to a significant drop in its stock price [1] Financial Performance - The company originally planned to release its third-quarter financial report on November 4, but it is now expected to be postponed until after market close on November 11 [1] - The impairment loss is related to certain long-term assets and is anticipated to have a "significant" impact on the third-quarter performance [1] Market Reaction - Following the announcement, Beyond Meat's stock fell by 11% in pre-market trading, and as of the report, it was down 8% [1]

Core Viewpoint - Beyond Meat has announced a delay in the release of its Q3 earnings report to quantify an impairment loss, leading to a significant drop in its stock price [1] Group 1: Financial Impact - The company originally planned to release its Q3 earnings on November 4, but it is now expected to be postponed until after market close on November 11 [1] - The impairment loss is related to certain long-term assets and is anticipated to have a "significant" impact on the company's Q3 performance [1] - The company currently cannot reasonably quantify the specific amount of the impairment loss, requiring additional time, resources, and effort for assessment [1] Group 2: Market Reaction - Following the announcement, the company's stock fell by 11% in pre-market trading, and as of the report, it was down 8% [1]

Core Insights - The company Tangrenshen has collaborated with Jiangnan University to research and develop artificial meat technology, although the related products have not yet been launched [2] Company Summary - Tangrenshen has engaged in research and development of artificial meat technology in partnership with Jiangnan University [2] - The company has indicated that the products stemming from this research are not currently available in the market [2]

Core Insights - The Chinese government has officially recognized biomanufacturing as one of the seven key future industries, alongside quantum technology and hydrogen energy, aiming to establish a high-tech industrial framework [2] - Biomanufacturing is positioned as a critical driver for industrial upgrading and high-quality economic development in China, comparable in importance to semiconductor manufacturing [2] Biomanufacturing Overview - Biomanufacturing utilizes industrial biotechnology to transform living cells into production facilities, converting renewable raw materials into high-value products such as pharmaceuticals, vaccines, biodegradable plastics, and synthetic fuels [2] Gene Editing Industry Analysis - Gene editing is a core technology supporting biomanufacturing, with applications in agriculture and disease treatment [3][4] - In agriculture, gene editing has been successfully applied to develop high-yield, disease-resistant crop varieties and improve livestock breeds [4] - In the medical field, gene editing shows potential in treating genetic diseases and cancers, providing new therapeutic options [4] Synthetic Biology Industry Analysis - Synthetic biology acts as an accelerator for biomanufacturing, impacting various sectors including energy, materials, and pharmaceuticals [8] - It is projected that 35% of petrochemical and coal chemical products could be replaced by biomanufactured products in the next decade, leading to significant economic implications [8] - The global market for synthetic biology in China was approximately $937 million in 2022, with expectations for rapid growth [11] Future Impact and Market Potential - Biomanufacturing is expected to revolutionize manufacturing processes, agricultural practices, and natural product sourcing [13] - By the end of the century, biomanufacturing could account for one-third of global manufacturing output, creating a market valued at $30 trillion [14]

Core Viewpoint - The company has collaborated with Jiangnan University on a plant-based meat project, but the related products have not yet been launched [1] Company Progress - The company has conducted preliminary research and developed relevant plant-based meat technologies in partnership with Jiangnan University [1]

Core Viewpoint - Xianle Health (300791.SZ) has confirmed that its business does not currently involve the field of artificial meat [1] Group 1 - The company has clarified its position regarding involvement in the artificial meat sector [1]